Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Focused Fund median (28 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Aug 2022 – 20 Aug 2026, limited by Edelweiss Focused Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Edelweiss Focused Fund | Nifty 500 |
|---|---|---|
| 03 Aug 2022 | ₹100.00 | ₹100.00 |
| 04 Dec 2022 | ₹107.37 | ₹107.30 |
| 06 Apr 2023 | ₹103.80 | ₹99.20 |
| 08 Aug 2023 | ₹118.18 | ₹113.92 |
| 09 Dec 2023 | ₹130.70 | ₹125.71 |
| 10 Apr 2024 | ₹148.44 | ₹140.58 |
| 11 Aug 2024 | ₹166.82 | ₹154.08 |
| 12 Dec 2024 | ₹176.90 | ₹156.31 |
| 14 Apr 2025 | ₹154.66 | ₹139.49 |
| 16 Aug 2025 | ₹169.27 | ₹152.44 |
| 17 Dec 2025 | ₹175.19 | ₹157.92 |
| 19 Apr 2026 | ₹173.80 | ₹153.71 |
| 20 Aug 2026 | ₹181.42 | ₹158.04 |
| Metric | Edelweiss · Direct NAV ₹18.19 Very High risk ★★★☆☆ | Category median Focused Fund · 28 funds |
|---|---|---|
| +4.89% | +5.84% | |
| +15.53% | +15.09% | |
| — | +13.35% | |
| — | +13.62% | |
| +15.86% | +15.49% | |
| +12.86% | — | |
| +17.86% | +16.73% | |
| — | +16.52% | |
| — | +16.05% | |
| Risk | ||
| 14.80% | 14.55% | |
| 0.61 | 0.57 | |
| 0.85 | 0.79 | |
| -17.15% | -34.05% | |
| Nifty 500 | — | |
| +3.24% | +3.16% | |
| 0.98 | 0.94 | |
| 106.5% | 104.9% | |
| 90.3% | 89.6% | |
| 0.83% | 1.06% | |
| ₹1,011Cr | ₹2,441Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 29% | 32% | |
| Amit Vora | — | |
| 03 Aug 2022 | — | |
| 29 | — | |
| 51.3% | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.